Carina bioTech
ARE CREATING A FUTURE THAT DEFEATS CANCER
Empowering patients to fight their cancer through next-generation
CAR-T technologies
About Carina Biotech
Clinical stage immuno-oncology company Carina Biotech is developing CAR-T and other adoptive cell therapies for the treatment of solid cancers. In addition to its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer, Carina has a deep pipeline of CAR-T programs.
Using its proprietary chemokine receptor platform, Carina aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects.
Carina also has a fully integrated, proprietary manufacturing process that has reduced manufacturing time and improved CAR-T cell quality, with the potential to deliver robust “serial-killing” CAR-T cells to patients.
MOD Cell Invaders
The objective of this project, was to teach children and young adults about the advances in T-Cell cancer therapy. To achieve this, Arterial developed their skill-set to include animation, 3D motion graphics and programming. The application of such skills were used in wall projections to create fully immersive experiences. They were also used in interactive games and floor projections.
